New-generation GLP-1 medicines in focus as pharma groups target side effects while patents start to expire
The side-effect profile of existing weight-loss drugs is now the stated target for pharma groups developing the next generation of GLP-1 medicines. The effort arrives as some patents on current treatments are starting to expire, giving the push commercial weight alongside whatever scientific merit the reformulations eventually carry.
Key takeaways
- Pharma groups developing the next generation of GLP-1 weight-loss drugs have stated that reducing the side effects of existing treatments is their target.
- The effort coincides with patents on some current GLP-1 treatments starting to expire, adding commercial motivation to the push.
- GLP-1 drugs are named for the glucagon-like peptide-1 hormone they act through and built their category on efficacy rather than tolerability.
- A next-generation drug that preserves the weight-loss mechanism while reducing side effects would gain fresh exclusivity and be harder for generics to undercut.
- As of now, no named company or molecule has been reported moving from stated direction to a clinical stage with an attached timeline.
The side-effect profile of existing weight-loss drugs is now the stated target for pharma groups developing the next generation of GLP-1 medicines. The effort arrives as some patents on current treatments are starting to expire, giving the push commercial weight alongside whatever scientific merit the reformulations eventually carry.
GLP-1 drugs, named for the glucagon-like peptide-1 hormone they work through, built their category on efficacy. The side effects were never part of the sales pitch; they arrived anyway. A next-generation product that preserves the weight-loss mechanism and reduces what patients have to tolerate on the way would be a distinct offering from the existing class, and a harder one to undercut with generic entry once patent protection fades.
The question worth asking is who the new generation serves first. Patent expiry compresses pricing on current drugs. A successor with fresh exclusivity restores margin. That dynamic has appeared in pharmaceutical development before, and there is no reason to assume this round is an exception.
What to watch is whether any named company or molecule moves from stated direction to a clinical stage with a timeline attached. For now, pharma groups are seeking. The patents are starting to expire. That is where the story sits.
Related reading
Filed by the newsroom of MarketPR on August 19, 2026. Source: ft.com. Indicative figures are not investment advice.